Summary
Johnson & Johnson (JNJ) filed an 8-K on April 28, 2022, detailing the outcomes of its Annual Meeting of Shareholders held on April 28, 2022. The primary focus of this filing is the voting results on various shareholder proposals and the election of directors. Key outcomes include the re-election of all 14 director nominees, the approval of the company's 2022 Long-Term Incentive Plan, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. The company also received advisory approval for its executive compensation policies. Notably, several shareholder proposals did not pass, including those related to a civil rights, equity, diversity & inclusion audit, a report on government financial support for COVID-19 vaccines, discontinuing global sales of talc-based baby powder, and linking CEO compensation to workforce pay. However, a shareholder proposal for a third-party racial justice audit was approved, indicating a nuanced view from shareholders on social and governance matters. Investors should note the broad support for JNJ's slate of directors and its incentive plans, alongside a mixed response to ESG-focused proposals.
Key Highlights
- 1All 14 director nominees were elected to the Board of Directors.
- 2Shareholders approved, on an advisory basis, the executive compensation philosophy and the compensation of named executive officers.
- 3The company's 2022 Long-Term Incentive Plan was approved by shareholders.
- 4PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2022.
- 5A shareholder proposal for a third-party racial justice audit was approved.
- 6Several shareholder proposals, including those on diversity audits, discontinuing talc-based baby powder sales, and linking CEO pay to workforce pay, were not approved.